$699 Million is the total value of Logos Global Management LP's 43 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 240.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | Buy | IVERIC BIO INC | $36,981,600 | +15.2% | 1,520,000 | +1.3% | 5.29% | +40.7% |
| BIIB | New | BIOGEN INC | $27,803,000 | – | 100,000 | +100.0% | 3.98% | – |
| ALLK | Buy | ALLAKOS INC | $24,638,164 | -44.7% | 5,536,666 | +4.7% | 3.53% | -32.4% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $20,244,000 | – | 200,000 | +100.0% | 2.90% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $16,083,000 | – | 150,000 | +100.0% | 2.30% | – |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $15,417,000 | +5.0% | 900,000 | +20.0% | 2.21% | +28.4% |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $14,586,000 | – | 150,000 | +100.0% | 2.09% | – |
| Buy | ASTRIA THERAPEUTICS INC | $13,897,968 | +7.9% | 1,044,960 | +20.8% | 1.99% | +31.8% | |
| GLPG | New | GALAPAGOS NVspon adr | $13,524,000 | – | 350,000 | +100.0% | 1.94% | – |
| New | DISC MEDICINE INC | $11,124,750 | – | 525,000 | +100.0% | 1.59% | – | |
| New | BIOHAVEN LTD | $9,562,000 | – | 700,000 | +100.0% | 1.37% | – | |
| New | ENLIVEN THERAPEUTICS INC | $8,786,915 | – | 401,229 | +100.0% | 1.26% | – | |
| New | STRUCTURE THERAPEUTICS INCsponsored ads | $8,326,500 | – | 350,000 | +100.0% | 1.19% | – | |
| MOR | Buy | MORPHOSYS AGsponsored ads | $5,940,000 | +84.4% | 1,500,000 | +66.7% | 0.85% | +125.5% |
| New | MINERALYS THERAPEUTICS INC | $4,698,000 | – | 300,000 | +100.0% | 0.67% | – | |
| ALGS | New | ALIGOS THERAPEUTICS INC | $874,000 | – | 1,000,000 | +100.0% | 0.12% | – |
| IMUX | New | IMMUNIC INC | $627,564 | – | 421,184 | +100.0% | 0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.